XML 64 R51.htm IDEA: XBRL DOCUMENT v3.25.1
Note 8 - Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 2 Months Ended 12 Months Ended
Sep. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
May 31, 2022
Feb. 28, 2025
Dec. 31, 2024
Dec. 31, 2023
Operating Lease, Monthly Rent Payment $ 4,700            
Operating Lease, Rent Expense, Annual Increase In Rent, Percent 2.00%            
Operating Lease, Weighted Average Remaining Lease Term (Year)           3 years 8 months 12 days  
Operating Lease, Weighted Average Discount Rate, Percent           9.60%  
Research and Development Expense           $ 17,729,000 $ 19,487,000
Stock Issued During Period, Value, New Issues           37,000 210,000
Employee Agreements, Termination Benefits Provided To Key Employees, Aggregate Amount           5,500,000  
The 2023 Bank Guarantee [Member] | Line of Credit [Member] | Letter of Credit [Member]              
Line of Credit Facility, Maximum Borrowing Capacity           200,000  
Long-Term Line of Credit           0  
Houston Pharmaceuticals, Inc [Member]              
Costs and Expenses, Related Party           234,000 234,000
Houston Pharmaceuticals, Inc [Member] | Consulting Agreement on Licensed Molecules [Member]              
Other Commitment       $ 43,500      
Houston Pharmaceuticals, Inc [Member] | Agreement Providing Access to Laboratory Equipment [Member]              
Other Commitment       $ 15,000      
Other Commitments, Cancellation Period (Year)       60 years      
Olympia Drive W Bellfort LLC [Member]              
Operating Lease, Rent Expense, Annual Increase In Rent, Percent     3.00%        
Houston Pharmaceuticals, Inc [Member]              
Percentage of Rent Payable By Co-Lessee     50.00%        
Percentage Of Sub-lease Income Allocable To Co-lessee     50.00%        
Sublease Income           49,000 49,000
MD Anderson [Member]              
License Agreements Expense           229,000 258,000
Research and Development Expense           2,049,000 $ 775,000
MD Anderson [Member] | Subsequent Event [Member]              
Payments For Research And Development Agreement         $ 0.3    
MD Anderson [Member] | Maximum [Member]              
License Agreement Annual License Fee           100,000  
MD Anderson [Member] | Maximum [Member] | Submission Of N D A And Receipt Of First Marketing Approval For Sale Of A Licensed Product [Member]              
Milestone Payment Liabilities           $ 600,000  
WPD Pharmaceuticals [Member] | License Termination [Member]              
Payments for Termination of Commitment   $ 700,000          
Stock Issued During Period, Value, New Issues   $ 800,000